The discovery of immune checkpoints, consisting of transmembrane ligand-receptor protein pairs that negatively regulate the CD8+ T-cell-mediated immune response by antigen-presenting cells (APCs) and by cancer cells, has enabled a fundamental advancement of cancer therapies (Korman et al, 2022). Here, CD8A is linked to cancer.